Gene therapy has also been approved for SMA treatment as a one-time intravenous injection of onasemnogene abeparvovec, which introduces the SMN1 transgene into motor neurons to replace the non-functional SMN1 gene [342]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.